Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview

Open access
Marra, Monica, Sordelli, Ignazio M, Lombardi, Angela, Lamberti, Monica, Tarantino, Luciano, Giudice, Aldo, Stiuso, Paola, Abbruzzese, Alberto, Sperlongano, Rossella, Accardo, Marina, Agresti, Massimo, Caraglia, Michele, Sperlongano, Pasquale · 2011 · Journal of Translational Medicine

Abstract

Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with multiple genetic aberrations. Several molecular pathways involved in the regulation of proliferation and cell death are implicated in the hepatocarcinogenesis. The major etiological factors for HCC are both hepatitis B virus (HBV) and hepatitis C virus infection (HCV). Continuous oxidative stress, which results from the generation of reactive oxygen species (ROS) by environmental factors or cellular mitochondrial dysfunction, has recently been associated with hepatocarcinogenesis. On the other hand, a distinctive pathological hallmark of HCC is a dramatic down-regulation of oxido-reductive enzymes that constitute the most important free radical scavenger systems represented by catalase, superoxide dismutase and glutathione peroxidase. The multikinase inhibitor sorafenib represents the most promising target agent that has undergone extensive investigation up to phase III clinical trials in patients with advanced HCC. The combination with other target-based agents could potentiate the clinical benefits obtained by sorafenib alone. In fact, a phase II multicenter study has demonstrated that the combination between sorafenib and octreotide LAR (So.LAR protocol) was active and well tolerated in advanced HCC patients. The detection of molecular factors predictive of response to anti-cancer agents such as sorafenib and the identification of mechanisms of resistance to anti-cancer agents may probably represent the direction to improve the treatment of HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1479-5876-9-171

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 230

Metadata

Authors
Marra, M., Sordelli, I. M., Lombardi, A., Lamberti, M., Tarantino, L., Giudice, A., Stiuso, P., Abbruzzese, A., Sperlongano, R., Accardo, M., Agresti, M., Caraglia, M., & Sperlongano, P.
Venue
Journal of Translational Medicine
Published
2011-10-10
Volume
9
Issue
1
Pages
171-171
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2136239966
Cited by
230
References
5
FWCI
9.89
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. https://app.cochat.ai/papers/10.1186/1479-5876-9-171
The paper
Marra, M., Sordelli, I. M., Lombardi, A., Lamberti, M., Tarantino, L., Giudice, A., Stiuso, P., Abbruzzese, A., Sperlongano, R., Accardo, M., Agresti, M., Caraglia, M., & Sperlongano, P. (2011). Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-9-171

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.